Tweak API Scheme For ‘Self-Reliant’ India, Says Industry
Dr Reddy’s Considers Investment
Executive Summary
Companies including Dr Reddy’s will consider investing in new API units if the Indian government tweaks its incentive scheme to permit exports of surplus production. Other suggested changes to the $1.3bn stimulus, aimed at enhancing the country's medicines security, include extending incentives to brownfield expansions and removing restrictions on a change in product mix.
You may also be interested in...
Will The $3bn Stimulus Amid COVID-19 Place Indian Cos Among Goliaths?
Following an INR69bn incentive scheme for APIs, the Indian government has come up with an INR150bn scheme for formulations and more. Will this $3bn push prove to be the one that companies like Sun Pharma and Aurobindo, currently at 36 and 48 respectively in Scrip 100 rankings, need to break into the top league?
Webinar Recording: India Supply Chain Issues Against The Backdrop Of COVID-19
Join Anju Ghangurde and Vibha Ravi in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series on COVID-19: Lessons Learned And A Path Forward.
Webinar Recording: India Supply Chain Issues Against The Backdrop Of COVID-19
Join Anju Ghangurde and Vibha Ravi in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series on COVID-19: Lessons Learned And A Path Forward.